GABA-B R2 Antibody [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # NB300-159IR
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Western Blot
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for GABA-B R2 Antibody [DyLight 755]
Immunogen
Synthetic peptide made to the 105 kDa GABAbR2 protein.
Reactivity Notes
Human. Other species not tested.
Localization
Cell Membrane
Specificity
Reacts to the N-terminal region of the GABA BR2 protein.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for GABA-B R2 Antibody [DyLight 755]
Application
Recommended Usage
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: GABA-B R2
Long Name
gamma-Aminobutyric Acid Type B Receptor Subunit 2
Alternate Names
GABABR2, GABBR2, GPR51, GPRC3B
Gene Symbol
GABBR2
Additional GABA-B R2 Products
Product Documents for GABA-B R2 Antibody [DyLight 755]
Product Specific Notices for GABA-B R2 Antibody [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...